EBV

20-Hydroxylucidenic acid E2 is a triterpene compound identified in Ganoderma ludicum. It significantly inhibits TPA-induced inflammation and suppresses TPA-induced EBV early antigen expression with an IC50 of 290 mol ratio 32 pmol TPA [indicating that the molar concentration of this compound is 290 times that of TPA (32 pmol) to achieve 50% inhibition of EBV early antigen expression]. This compound is applicable in anti-inflammatory and anticancer research.

Lobucavir (BMS-180194; SQ 34514) is a nucleoside analogue and an antiviral agent with broad-spectrum activity against various viruses, including HBV, HIV AIDS, and α, β, and γ herpesviruses (including CMV, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus).

L2P4 is a peptide-based fluorescent probe targeting EBNA1 that inhibits the homodimerization of EBNA1 and selectively suppresses the growth of EBV+ tumors. Exhibiting cytotoxicity in EBV-positive C666-1 cells, L2P4 has an LC50 of 46.4 μM.